Benefit of prophylactic pelvic irradiation in intermediate-risk prostate cancer: A multicenter retrospective study (iPPAPI)
In intermediate-risk PCa, WPRT did not improve RFS or OS compared with prostate-only RT but was associated with an increased risk of severe GI toxicity.
Authors
- Yazid Belkacémi
- C. Durdux
- F. Huguet (ORCID: https://orcid.org/0000-0002-5302-5784)
- L. Quéro (ORCID: https://orcid.org/0000-0002-8781-2540)
- Christophe Hennequin (ORCID: https://orcid.org/0000-0002-4528-927X)
- Jean‐Emmanuel Bibault (ORCID: https://orcid.org/0000-0002-1728-6776)
- Rafik Nebbache
- Cyrus Chargari (ORCID: https://orcid.org/0000-0003-0119-3695)
- C. Raynaud (ORCID: https://orcid.org/0009-0009-0526-8632)
Institutions
- Inserm (FR)
- Institut Gustave Roussy (FR)
- Sorbonne Université (FR)
- Centre de Recherche des Cordeliers (FR)
- Hôpital Européen (FR)
- Pitié-Salpêtrière Hospital (FR)
- Hôpitaux Universitaires Henri-Mondor (FR)
- Hôpital Saint-Louis (FR)
- Institut Mondor de Recherche Biomédicale (FR)
- Hôpital Tenon (FR)
Publication Details
- Journal
- Clinical and Translational Radiation Oncology
- Published
- 2025-12-06
- DOI
- https://doi.org/10.1016/j.ctro.2025.101093
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00